Checkmate Pharmaceuticals, Inc. SEC Filings

Filed On	Filing
10 Jun 2022	15-12B
07 Jun 2022	SC 13G/A
07 Jun 2022	SCHEDULE 13D - AMENDMENT NO. 1
03 Jun 2022	SC 13D/A
03 Jun 2022	SCHEDULE 13D - CHECKMATE PHARMACEUTICALS, INC.
01 Jun 2022	EFFECT
31 May 2022	25-NSE
31 May 2022	Form 4: Powell Michael, Director Disposed of 70,030 Stock Option (Right to Buy) (Disposition to Issuer)
31 May 2022	Form 4: Flaherty Keith T., Director Disposed of 36,778 Stock Option (Right to Buy) (Disposition to Issuer)
31 May 2022	Form 4: Isacoff Oren, Director Disposed of 30,030 Stock Option (Right to Buy) (Disposition to Issuer)
31 May 2022	Form 4: Colabuono Peter, Director Disposed of 30,030 Stock Option (Right to Buy) (Disposition to Issuer)
31 May 2022	Form 4: Yan Joy, Director Disposed of 20,061 Stock Option (Right to Buy) (Disposition to Issuer)
31 May 2022	Form 4: Dolski Robert, Chief Financial Officer Disposed of 278,480 Stock Option (Right to Buy) (Disposition to Issuer)
31 May 2022	Form 4: Wooldridge James, Chief Medical Officer Disposed of 429,814 Stock Option (Right to Buy) (Disposition to Issuer)
31 May 2022	Form 4: Wigginton Jon Marc, Director Disposed of 20,061 Stock Option (Right to Buy) (Disposition to Issuer)
31 May 2022	Form 4: Fuhrman Alan, Director Disposed of 279,437 Stock Option (Right to Buy) (Disposition to Issuer)
31 May 2022	Form 4: Bash Alan, Director Disposed of 575,000 Stock Option (Right to Buy) (Disposition to Issuer)
31 May 2022	S-8 POS
31 May 2022	S-8 POS
31 May 2022	S-8 POS

Comments